期刊
NEUROLOGY
卷 79, 期 19, 页码 1944-1950出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182735e9a
关键词
-
资金
- Department of Veterans Affairs [1I01BX000531]
- National Institutes of Health [P30 AG008017, P30 AG028383, P30 AG010124, P30 AG010161, P50 AG005131, P50 NS062684, P50 AG005136, P50 AG005133, R01 AG007584, R01 AG010845, R01 AG015819, R01 AG017917, R01 NS048595, R01 NS065070, U01 AG006781, U01 AG016976]
- NARSAD
- American Parkinson Disease Association
- Michael J. Fox Foundation
- Northwest Collaborative Care
- Danone Research B.V.
- Illinois Department of Public Health
- Robert C. Borwell Endowment Fund
- Avid Radiopharmaceuticals, Inc.
- Alzheimer's Association
- Johnson Johnson
- Roche
- Bristol Myers Squibb
- Pfizer
- Elan Corporation
- Janssen
- Medivation, Inc.
- Danone
- NIH/NIA
- National Institute on Aging
- Takeda Pharmaceutical Company, Ltd.
- NIH (NIA, NINDS)
- Marian S. Ware Alzheimer Program
- Integra-Gen
- NIH (NIA, NIMH)
- Autism Genome Project
- Autism Speaks
- CurePSP
- Rainwater Foundation
- Peebler PSP Research Foundation
- Parkinson's Disease Foundation
Objectives: Mutations in the GBA gene occur in 7% of patients with Parkinson disease (PD) and are a well-established susceptibility factor for PD, which is characterized by Lewy body disease (LBD) neuropathologic changes (LBDNCs). We sought to determine whether GBA influences risk of dementia with LBDNCs, Alzheimer disease (AD) neuropathologic changes (ADNCs), or both. Methods: We screened the entire GBA coding region for mutations in controls and in subjects with dementia and LBDNCs and no or low levels of ADNCs (pure dementia with Lewy bodies [pDLB]), LBDNCs and high-level ADNCs (LBD-AD), and high-level ADNCs but without LBDNCs (AD). Results: Among white subjects, pathogenic GBA mutations were identified in 6 of 79 pDLB cases (7.6%), 8 of 222 LBD-AD cases (3.6%), 2 of 243 AD cases (0.8%), and 3 of 381 controls (0.8%). Subjects with pDLB and LBD-AD were more likely to carry mutations than controls (pDLB: odds ratio [OR] = 7.6; 95% confidence interval [CI] = 1.8-31.9; p = 0.006; LBD-AD: OR = 4.6; CI = 1.2-17.6; p = 0.025), but there was no significant difference in frequencies between the AD and control groups (OR = 1.1; CI = 0.2-6.6; p = 0.92). There was a highly significant trend test across groups (chi(2)(1) = 19.3; p = 1.1 x 10(-5)), with the likelihood of carrying a GBA mutation increasing in the following direction: control/AD < LBD-AD < pDLB. Conclusions: GBA is a susceptibility gene across the LBD spectrum, but not in AD, and appears to convey a higher risk for PD and pDLB than for LBD-AD. PD and pDLB might be more similar to one another in genetic determinants and pathophysiology than either disease is to LBD-AD. Neurology (R) 2012;79:1944-1950
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据